Genelux
Genelux Corporation is a privately-held, clinical-stage biopharmaceutical company that has developed a proprietary oncolytic virus-based technology platform and a deep pipeline of products with broad applications for cancer detection and therapy. GL-ONC1 the company’s lead oncology product candidate is an attenuated vaccinia virus (Lister strain) that results in dramatic regression and elimination of a wide range of solid tumors in animals without damaging healthy tissues or organs. GL-ONC1 encodes Green Fluorescent Protein (GFP) to enable highly selective imaging of tumors and metastases as an aid in the diagnosis and staging of cancer. GL-ONC1 is currently under evaluation in Phase I/II human clinical trials in the United States and Europe, and additional US and European-based trials are set to begin in the near future. GL-ONC1 is proving well-tolerated with minimal side effects and showing early signs of anti-tumor activity.
Tech Stack (26 technologies)
Frequently Asked Questions
What technologies does Genelux use?+
Genelux uses 26 technologies including Facebook Pixel, Google Analytics, Google Tag Manager.
What industry is Genelux in?+
Genelux operates in the Biopharma industry.
Where is Genelux based?+
Genelux is headquartered in United States.
Explore More
Need this data at scale?
Get ready-to-use datasets: companies, technologies, and tech adoption signals across 3M+ websites.
Browse DatasetsData last updated: June 2026